Cart
sales@molnova.com
PSNCBAM-1
CAS No. 877202-74-9
PSNCBAM-1( PSNCBAM 1 | PSNCBAM1 )
Catalog No. M27917 CAS No. 877202-74-9
PSNCBAM-1 is a CB1 receptor negative allosteric modulator (EC50 = 0.1 μM) with hypophagic effects in vivo. PSNCBAM-1 can be used for obesity studies.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 133 | Get Quote |
|
| 10MG | 195 | Get Quote |
|
| 25MG | 323 | Get Quote |
|
| 50MG | 480 | Get Quote |
|
| 100MG | 692 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePSNCBAM-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionPSNCBAM-1 is a CB1 receptor negative allosteric modulator (EC50 = 0.1 μM) with hypophagic effects in vivo. PSNCBAM-1 can be used for obesity studies.
-
DescriptionPSNCBAM-1 is a CB1 receptor negative allosteric modulator (EC50 = 0.1 μM) with hypophagic effects in vivo. PSNCBAM-1 can be used for obesity studies.
-
In Vitro——
-
In Vivo——
-
SynonymsPSNCBAM 1 | PSNCBAM1
-
PathwayGPCR/G Protein
-
TargetCannabinoid Receptor
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number877202-74-9
-
Formula Weight392.89
-
Molecular FormulaC22H21ClN4O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESClc1ccc(NC(=O)Nc2cccc(c2)-c2cccc(n2)N2CCCC2)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Bajpai VK, et al. Antibacterial Action of Jineol Isolated from Scolopendra subspinipes mutilans against Selected Foodborne Pathogens. Front Microbiol. 2017 Mar 28;8:552.
molnova catalog
related products
-
CB1 antagonist 2
CB1 antagonist 2 is caimabinoid 1 (CB1) antagonist extracted from patent WO2016184310A1, compound 3. Which inhibits CB1 in vivo with an IC50 of 25.5 nM.
-
PrNMI
PrNMI is a peripherally restricted cannabinoid 1 receptor (CB1R) agonist.
-
Anandamide
Anandamide, an immune modulator, acts via not only cannabinoid receptors (CB1 and CB2) but also other targets (e.g., GPR18/GPR55) in the central nervous system.
